GFR decline as an end point in trials of CKD: a viewpoint from the FDA

Am J Kidney Dis. 2014 Dec;64(6):836-7. doi: 10.1053/j.ajkd.2014.09.006. Epub 2014 Oct 31.

Authors

Aliza Thompson¹, John Lawrence², Norman Stockbridge²

Affiliations

¹ Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland. Electronic address: Aliza.Thompson@fda.hhs.gov.
² Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.

PMID: 25446026
DOI: 10.1053/j.ajkd.2014.09.006

No abstract available

Publication types

Editorial
Comment

MeSH terms

Education / standards*
Endpoint Determination / standards*
Foundations / standards*
Glomerular Filtration Rate / physiology*
Humans
Renal Insufficiency, Chronic / diagnosis*
United States Food and Drug Administration / standards*